Elinafide bismesylate | 199330-45-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 英文名称: Elinafide bismesylate
• 英文别名: 2-[2-[3-[2-(1,3-dioxobenzo[de]isoquinolin-2-yl)ethylamino]propylamino]ethyl]benzo[de]isoquinoline-1,3-dione;methanesulfonic acid
• CAS: 199330-45-5
• 化学式: C33H36N4O10S2
• 分子量: 712.8
• InChiKey: ZDEINNOMAWXNKF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.46
• 重原子数：
  49
• 可旋转键数：
  10
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  224
• 氢给体数：
  4
• 氢受体数：
  12

文献信息

• Heterocyclic-substituted bis-1,8 naphthalimide compounds, antibody drug conjugates, and methods of use
  申请人：Gazzard J. Lewis

  公开号：US20060182751A1

  公开（公告）日：2006-08-17

  The invention relates to bis 1,8 naphthalimide compounds including antibody drug conjugate (ADC) compounds represented by Formula I: Ab-(L-D) p I where one or more 1,8 bis-naphthalimide drug moieties (D) having Formulas IIa and IIb are covalently linked, through the wavy line, by a linker (L) to an antibody (Ab). The invention also relates to heterocyclic-substituted 1,8 bis-naphthalimide compounds having Formula XV The invention also relates to pharmaceutical compositions comprising an effective amount of a Formula I ADC or Formula XV heterocyclic-substituted 1,8 bis-naphthalimide compound for treatment of hyperproliferative disorders and other disorders. The invention also relates to methods for killing or inhibiting the proliferation of tumor cells or cancer cells including administering to a patient an effective amount of a Formula I ADC or Formula XV compound.

  本发明涉及双 1,8-萘二甲酰亚胺化合物，包括由式 I 表示的抗体药物共轭物 (ADC) 化合物： Ab-(L-D) p I 其中具有式 IIa 和 IIb 的一个或多个 1,8-双萘二亚胺药物分子（D）通过连接体 （L）与抗体（Ab）通过波浪线共价连接。 本发明还涉及具有式 XV 的杂环取代的 1，8 双萘二甲酰亚胺化合物。 本发明还涉及药物组合物，该药物组合物包含有效量的式ⅠADC或式XV杂环取代的1,8-双萘二亚胺化合物，用于治疗过度增殖性疾病和其他疾病。本发明还涉及杀死或抑制肿瘤细胞或癌细胞增殖的方法，包括向患者施用有效量的式ⅠADC或式XV化合物。
• CONJUGATES OF 1,8-BIS-NAPHTHALIMIDES WITH AN ANTIBODY
  申请人：GENENTECH, INC.

  公开号：EP1817059A2

  公开（公告）日：2007-08-15
• HETEROCYCLIC-SUBSTITUTED BIS-1,8 NAPHTHALIMIDE COMPOUNDS, ANTIBODY DRUG CONJUGATES, AND METHODS OF USE
  申请人：GENENTECH, INC.

  公开号：EP1954317A2

  公开（公告）日：2008-08-13
• Antibody drug conjugates and methods
  申请人：Gazzard J. Lewis

  公开号：US20070134243A1

  公开（公告）日：2007-06-14

  The invention relates to antibody drug conjugate (ADC) compounds represented by Formula I: Ab-(L-D) p I where one or more 1,8 bis-naphthalimide drug moieties (D) having Formulas IIa and IIb are covalently linked by a linker (L) to an antibody (Ab). The invention also relates to pharmaceutical compositions comprising an effective amount of a Formula I ADC for treatment of hyperproliferative disorders and other disorders. The invention also relates to methods for killing or inhibiting the multiplication of a tumor cell or cancer cell including administering to a patient an effective amount of a Formula I ADC.
• US7947839B2
  申请人：——

  公开号：US7947839B2

  公开（公告）日：2011-05-24